Purchase this article with an account.
E. S. Lopez, J. O. Croxatto, A. Kvanta, J. E. Gallo; Effect of Bevacizumab (Avastin) and Suramin in a Rabbit Model of Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1717.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyse the ability of Bevacizumab (Avastin) and Suramin to inhibit Corneal Neovascularization (NV) in a corneal alkali burn model.
Corneal NV was induced in nine White New Zealand rabbits, applying a filter paper disc soaked in 1M Na (OH) on the central cornea. Two groups made up of three rabbits each were treated after injury with intravenous Bevacizumab (5mg/kg) and iv Suramin (20mg/kg), respectively. The remaining three rabbits constituted the control group. Digital photographs were taken at days 9, 15 and 21. NV index(NVI) was calculated using the Imagej program. Neovessels formation was quantified given a score from 0 to 4 to each quadrant according to the centripetal growth of the longest vessel. Scores of the four quadrants were summed to obtain the NVI.
Nine days after injury, the NVI was higher in the control group (mean NVI= 6,6) than in the treated groups. Bevacizumab significantly reduced neovessels formation (mean NVI= 5,3) compared with control animals (mean NVI= 13) after 21 days. Although both drugs diminished neovessels development, a much more reduction was found using Bevacizumab (mean NVI= 5,3) than with Suramin (mean NVI= 7) 21 days after injury.
Intravenous Bevacizumab (Avastin) and Suramin could be considered therapeutic agents for reducing corneal neovascularization. A combined treatment of both drugs is being analysed.
This PDF is available to Subscribers Only